Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03356782 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jun 1, 2026 to Jun 1, 2027
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Study description expanded, about 66 words
    • Site details revised
    v6
  2. Primary completion date: Nov 30, 2023 to Dec 31, 2029
    • Start date: Dec 1, 2017 to Jun 1, 2026
    • Study completion date: Dec 31, 2023 to Dec 31, 2030
    • Site contact updated
    v5
  3. Primary completion date: Oct 31, 2019 to Nov 30, 2023
    • Study completion date: Dec 31, 2020 to Dec 31, 2023
    v4
  4. Re-verified, no change to tracked fieldsv3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines CAR T cells and IgT cells to treat sarcoma.
Trial Details
NCT Number NCT03356782
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions
(from sponsor)		 Sarcoma, Osteoid Sarcoma, Ewing Sarcoma
Related terms Bone Neoplasms, Diabetes Mellitus, Insulin-Dependent, 12, Sarcoma, Sarcoma, Ewing
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov